KalVista Pharmaceuticals ( NASDAQ:KALV) has announced it has presented data at he C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary.

As quoted in the press release:

“KVD900 is an oral, novel, potent and selective inhibitor of plasma kallikrein, a validated target in hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “We believe KVD900 represents a new therapeutic opportunity to rapidly halt HAE attacks at their earliest sign and we look forward to seeing the Phase 2 data late this year.”

KalVista’s oral presentation and poster showed:

• KVD900 rapidly reached high levels of drug exposure and was well tolerated without related gastrointestinal adverse events
• KVD900 successfully interrupts the contact activation system’s positive feedback loop between plasma kallikrein, prekallikrein, and FXII
• Within 10 minutes an inhibitory effect on plasma kallikrein activity was detected with KVD900 in undiluted plasma and within 20 minutes it was by greater than 95%. KVD900 provided critical high molecular weight kininogen (HK) cleavage protection for at least 10 hours

Click here to read the full press release.